🇺🇸 FDA

Intelligence · Clinical Pipeline

First People's Hospital Pipeline

All ClinicalTrials.gov programs at First People's Hospital — phase, modality, and trial IDs.

Programs
375

Quick answer

First People's Hospital has 375 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. chidamide + camrelizumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  2. chidamide，fulvestrant

    The First People's Hospital of Lianyungang

    Hormone Receptor-positive Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  3. cisplatin and 5-Fu combined with nimotuzumab

    The First People's Hospital of Lianyungang

    Stage IV Nasopharyngeal Carcinoma

    phase 2 small molecule completed

    1 trial

  4. compound diclofenac sodium

    The First People's Hospital of Lianyungang

    Acute Abdominal Pain

    phase 2 small molecule active

    1 trial

  5. experimental group x-MAP

    The First People's Hospital of Lianyungang

    Metastatic Colorectal Cancer (mCRC)

    phase 2 other active

    1 trial

  6. fecal microbiota

    The First People's Hospital of Lianyungang

    Insomnia Chronic

    phase 2 mab completed

    1 trial

  7. five - flavor sophora flavescens enteric - coated capsules plus glutamine and warm - water sitz baths

    The First People's Hospital of Lianyungang

    Radiation - Induced Proctitis

    phase 2 small molecule active

    1 trial

  8. fulzerasib

    The First People's Hospital of Lianyungang

    Resectable NSCLC

    phase 2 small molecule active

    1 trial

  9. gemcitabine and oxaliplatin.

    The First People's Hospital of Lianyungang

    Gallbladder Carcinoma

    phase 2 small molecule active

    1 trial

  10. golidocitinib

    The First People's Hospital of Lianyungang

    IrAE

    phase 2 small molecule active

    1 trial

  11. induction chemotherapy and immunotherapy

    The First People's Hospital of Lianyungang

    ESCC

    phase 2 small molecule completed

    1 trial

  12. intravenous infusion (IV) of Adebrelimab (ADE)

    The First People's Hospital of Lianyungang

    Advanced Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  13. lenalidomide combined with rituximab

    The First People's Hospital of Lianyungang

    Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  14. mFOLFOXIRI

    The First People's Hospital of Lianyungang

    Locally Advanced Rectal Cancer

    phase 2 small molecule active

    1 trial

  15. megestrol acetate oral suspension + serplulimab + SOX

    The First People's Hospital of Lianyungang

    Stage III Gastric Cancer

    phase 2 small molecule active

    1 trial

  16. mitoxantrone hydrochloride liposome

    The First People's Hospital of Lianyungang

    Relapsed/Refractory Acute Myeloid Leukaemia

    phase 2 small molecule active

    2 trials

  17. nanoparticle albumin-bound paclitaxel/carboplatin

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  18. ondansetron

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  19. online adaptive radiotherapy

    The First People's Hospital of Lianyungang

    Cervical Cancer

    phase 2 other active

    1 trial

  20. orelabrutinib combined with rituximab regimen

    The First People's Hospital of Lianyungang

    Marginal Zone Lymphoma(MZL)

    phase 2 small molecule active

    1 trial

  21. osimertinib mesylate tablets and anlotinib hydrochloride capsules

    The First People's Hospital of Lianyungang

    Non Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  22. pembrolizumab

    The First People's Hospital of Lianyungang

    Advanced Non-squamous Non-small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  23. penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin

    The First People's Hospital of Lianyungang

    Lymphoma, Large B-Cell, Diffuse

    phase 2 small molecule active

    1 trial

  24. pharmorubicin or pirarubicin

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  25. placebo

    The First People's Hospital of Lianyungang

    COVID-19 Thalidomide

    phase 2 small molecule active

    1 trial

  26. pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy

    The First People's Hospital of Lianyungang

    HER2-positive Breast Cancer

    phase 2 small molecule active

    1 trial

  27. recombinant humanized anti-CD25 monoclonal antibody

    The First People's Hospital of Lianyungang

    Transfusion Dependent Thalassemia

    phase 2 small molecule active

    1 trial

  28. retinal pigment epithelium transplantation

    The First People's Hospital of Lianyungang

    Dry Age-related Macular Degeneration

    phase 2 mab active

    1 trial

  29. rituximab /Dexamethasone/cyclophosphamide

    The First People's Hospital of Lianyungang

    Treatment

    phase 2 small molecule active

    1 trial

  30. sintilimab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  31. sintilimab

    The First People's Hospital of Lianyungang

    Colorectal Neoplasms

    phase 2 small molecule active

    1 trial

  32. ssCART-19

    The First People's Hospital of Lianyungang

    Relapsed or Refractory Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

  33. ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia, Adult B-Cell

    phase 2 mab active

    1 trial

  34. surufatinib + fulvestrant + chidamide

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  35. tauroursodeoxycholic acid (TUDCA)

    The First People's Hospital of Lianyungang

    Metabolic Dysfunction-Associated Steatotic Liver Disease Infant Development

    phase 2 small molecule active

    1 trial

  36. toripalimab

    The First People's Hospital of Lianyungang

    Malignant Melanoma

    phase 2 small molecule active

    1 trial

  37. trifluridine/tipiracil combined with fufuquitinib

    The First People's Hospital of Lianyungang

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  38. unrelated umbilical cord blood

    The First People's Hospital of Lianyungang

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  39. veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG)

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does First People's Hospital have?

375 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.